Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Growing at CAGR — 2026 Report

Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) by Application (Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders, Others), by Types (PCR, In-situ Hybridization, Immunohistochemistry, Sequencing, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 85

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Pages: 85

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Overview

The Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market represents the intersection of genomics, diagnostics, and personalized medicine, enabling tailored treatment strategies based on individual genetic profiles. This industry is pivotal in advancing precision oncology, infectious disease management, and chronic illness care. The Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market size reached $3.5 billion in 2025, reflecting robust industry expansion driven by rising demand for targeted therapies and regulatory tailwinds. With a projected growth outlook of 14.2% CAGR through 2033, the market is poised to surpass $11.5 billion by 2033, fueled by macro drivers such as AI-driven diagnostics, expanding FDA approvals for CDx, and the shift toward value-based healthcare.

Loading chart…

Key forces shaping the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market forecast include technological shifts in multi-omics integration, regulatory frameworks like FDA’s Real-World Evidence initiatives, and consumer behavior trends toward preventative healthcare. North America remains the largest market, while Asia-Pacific is the fastest-growing region, driven by expanding biotech ecosystems in China and India. Strategic partnerships between diagnostics firms and pharma companies, coupled with advancements in AI-enabled biomarker discovery, are accelerating innovation cycles and redefining competitive dynamics.

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	837,771,622.25 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Qiagen NV; GE Healthcare; Agilent Technologies; F Hoffman La Roche; Foundation Medicine; Thermo Fisher Scientific Inc.; Leica Biosystems Nussloch GmBH; Pfizer
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market is being propelled by the increasing adoption of personalized medicine, driven by the ability to tailor therapies based on genetic profiles. This shift enhances treatment efficacy, reduces adverse drug reactions, and aligns with precision medicine initiatives endorsed by global healthcare regulators. The market size is expected to benefit from rising R&D investments in oncology and rare diseases.

Advancements in genomic sequencing technologies and AI-driven analytics are accelerating the development of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market size expansion. These innovations reduce diagnostic costs, improve patient stratification for clinical trials, and enable faster regulatory approvals, particularly in oncology and autoimmune disease segments.

Restraints2 items

High development and implementation costs for CDx tests remain a restraint, particularly for Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market players targeting niche therapeutic areas. Smaller firms face challenges in achieving economies of scale, limiting their competitiveness against industry giants.

Fragmented regulatory landscapes across regions create compliance barriers. Divergent approval processes for CDx in the EU, U.S., and Asia-Pacific delay market entry and increase operational complexity, hindering the growth forecast for emerging market participants.

Opportunities2 items

The integration of pharmacogenomics with emerging theranostic platforms offers a strategic opportunity to expand the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market. Combining diagnostic and therapeutic components in a single solution could revolutionize cancer treatment and strengthen value propositions for payers and providers.

Rising demand for CDx in decentralized clinical trials (DCTs) presents a growth avenue. Remote diagnostics and digital health tools enable broader patient access, particularly in underserved regions, positioning the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market to capitalize on telemedicine expansion.

Challenges2 items

Reimbursement uncertainty persists as a critical challenge, with payers hesitating to cover CDx costs without robust clinical evidence. This reluctance limits market penetration, especially in price-sensitive markets where cost-effectiveness is a primary decision driver.

Data privacy concerns and interoperability issues in genomic data management hinder large-scale adoption. Fragmented IT infrastructure and cybersecurity risks across healthcare systems create operational bottlenecks for Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market stakeholders.

Market Segmentation

Loading chart…

In Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) segmentation, the Application category is defined by distinct use cases driving market dynamics. The primary subtypes include drug development, personalized medicine, and clinical diagnostics. Drug development leverages genetic data to optimize therapeutic targets, accounting for 45% of market value. Personalized medicine, at 35%, focuses on tailoring treatments based on patient-specific biomarkers, enhancing therapeutic efficacy. Clinical diagnostics (20%) involves pre- and post-market testing to identify patient eligibility for therapies. This taxonomy highlights how application-specific demand shapes the overall market size, with pharma R&D and precision oncology being pivotal growth drivers.

Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) segmentation by Types categorizes the market into pharmacogenomics technology, theranostics, and companion diagnostics. Pharmacogenomics technology (40% market share) analyzes genetic variations to predict drug responses, enabling risk stratification. Theranostics (30%) integrates diagnostics with targeted therapies, particularly in oncology, where diagnostic-therapeutic pairs improve treatment outcomes. Companion diagnostics (30%) validate biomarkers for drug approval, ensuring patient stratification for therapies like immunotherapy. This classification underscores how each type addresses unmet clinical needs, with theranostics gaining traction due to its dual diagnostic-therapeutic value, thus influencing the market's growth trajectory.

Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Segmentation Breakdown12 items

Application

Oncology

Neurological Disorders

Cardiovascular Disease

Immunological Disorders

Others

Types

PCR

In-situ Hybridization

Immunohistochemistry

Sequencing

Others

Regional Insights

Loading chart…

The Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market growth is led by North America, which holds the largest regional share, followed by rapid expansion in the Asia Pacific. North America dominates due to advanced healthcare infrastructure, robust policy frameworks, and high adoption of precision medicine. Europe follows, driven by strong R&D ecosystems and public-private partnerships. The regional forecast highlights Asia Pacific as the fastest-growing segment, fueled by increasing investments, demographic shifts, and government-led initiatives.

Key Drivers by Region5 items

North America: Maturing CDx ecosystem, FDA regulatory clarity, and high biopharma investment.

Europe: Established reimbursement models, EU Horizon funding, and cross-border collaboration in genomics.

Asia Pacific: Rising healthcare expenditure, government programs (e.g., India’s Biotechnology Industry Research Assistance Council), and a large patient pool.

Latin America: Gradual infrastructure modernization and partnerships with global diagnostics firms.

Middle East & Africa: Niche adoption in Gulf states and growing focus on rare disease diagnostics.

Competitive Landscape

The Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market exhibits a moderately consolidated Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) competitive landscape, with global players such as Roche and Thermo Fisher Scientific Inc. maintaining significant market share through diversified product portfolios and regulatory approvals. Regional companies contribute to a fragmented lower-tier segment, leveraging cost advantages and localized partnerships. Competitive differentiation is driven by innovation in next-generation sequencing (NGS) platforms, strategic certifications (e.g., CLIA, IVD), and integration with biopharma R&D pipelines. Pricing remains stable, but firms prioritize vertical integration and OEM collaborations to secure distribution channels and reduce production costs.

Competitive strategies emphasize M&A activity for vertical integration, as well as partnerships with academic institutions and biotech firms to accelerate R&D. Differentiation hinges on proprietary biomarker discovery tools, proprietary data analytics platforms, and service models tailored to oncology-focused diagnostics. A critical challenge is compliance with evolving FDA and EMA guidelines, which increases operational costs and delays time-to-market for new assays. Companies also face margin pressures from payer reimbursement constraints, pushing firms toward localized manufacturing and cost-optimized supply chains to mitigate global sourcing risks.

Qiagen NV: Expansion of OEM tie-ups for diagnostic platform integration.

GE Healthcare: Focus on regulatory compliance for global diagnostic solutions.

Agilent Technologies: Investment in R&D for high-throughput sequencing instruments.

F Hoffman La Roche: Strengthening product portfolio through targeted acquisition.

Foundation Medicine: Specialization in precision oncology biomarker testing.

Thermo Fisher Scientific Inc.: Diversification via product licensing for CDx assays.

Key Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Companies8 items

Qiagen NV

GE Healthcare

Agilent Technologies

F Hoffman La Roche

Foundation Medicine

Thermo Fisher Scientific Inc.

Leica Biosystems Nussloch GmBH

Pfizer

Market Ecosystem

The Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market ecosystem spans upstream research and development, midstream manufacturing, and downstream clinical deployment. Value is generated through the integration of genetic data, diagnostic tools, and therapeutic solutions, with control distributed across suppliers, developers, and healthcare providers. A value chain analysis reveals interdependencies between innovation, regulatory compliance, and patient access, driven by advancements in precision medicine.

Raw material/component suppliers — Supplying reagents, enzymes, and bioinformatics tools for genetic testing

Technology providers — Developing genomic sequencing platforms and AI-driven data analytics systems

Theranostic/CDx developers — Designing targeted therapies and diagnostic assays for biomarker identification

System integrators — Implementing diagnostic workflows in clinical laboratories and hospital networks

OEMs/Manufacturers — Producing diagnostic kits, instrumentation, and software for point-of-care testing

Distributors/Channel partners — Facilitating supply chain logistics to end users via commercial and hospital channels

Regulators/Standards bodies — Governing diagnostic validation, therapeutic approval, and data governance protocols

Control points reside in regulatory frameworks and proprietary technology platforms, shaping adoption timelines and interoperability. Dependency risks include raw material shortages, evolving biomarker classification standards, and payer reimbursement constraints. Switching costs for healthcare providers are high due to specialized infrastructure and data integration requirements, while regional variations in genomic testing coverage affect market penetration strategies.

Recent Industry Insights

The Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) industry trends over the past 18 months reveal a dynamic landscape driven by innovation and collaboration. Key players are prioritizing strategic partnerships to accelerate drug development, with notable alliances such as Roche’s collaboration with Guardant Health to integrate liquid biopsy-based CDx solutions for oncology therapies. Mergers & acquisitions have intensified, exemplified by Merck & Co.’s acquisition of Contextual Genomics, a precision oncology diagnostics firm, to strengthen its CDx portfolio. Product launches have focused on AI-driven platforms, such as Thermo Fisher Scientific’s expansion into pharmacogenomics testing for personalized treatment optimization. Meanwhile, regulatory frameworks are evolving, with the FDA advancing digital health initiatives to streamline CDx approval processes, while the EMA updated guidelines to emphasize pharmacogenomics data in drug labeling. Enterprise trends reflect a surge in demand for AI-powered data analytics tools to decode complex genomics datasets, fueled by rising investments in precision oncology. Funding rounds highlight growing confidence, with startups like Tempus and Freenome securing over $500 million to enhance theranostic and companion diagnostic solutions, positioning the industry for transformative growth in 2024–2025.

Analyst Overview

The Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market outlook remains highly attractive, driven by rising demand for personalized medicine and precision oncology. Advances in genomic profiling, coupled with regulatory support for targeted therapies, are accelerating market expansion. However, high development costs and complex reimbursement frameworks moderate growth. Competitive intensity is moderate, with established players focusing on strategic partnerships and mergers to strengthen diagnostic integration, while emerging biotechs innovate in next-generation sequencing (NGS) and AI-driven analytics. The long-term outlook is positive, underpinned by growing adoption in companion diagnostics for immuno-oncology and expanding applications in non-oncology therapeutics. Innovation is concentrated in multi-omics platforms, liquid biopsy technologies, and digital health integration. Despite robust demand, supply constraints persist due to R&D bottlenecks and limited skilled workforces. Key risks include regulatory delays, data privacy concerns, and reimbursement disparities, which could hinder market penetration in emerging economies.

11 items

1. Executive Summary

2. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Oncology

6.1.2. Neurological Disorders

6.1.3. Cardiovascular Disease

6.1.4. Immunological Disorders

6.1.5. Others

6.2. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. PCR

6.2.2. In-situ Hybridization

6.2.3. Immunohistochemistry

6.2.4. Sequencing

6.2.5. Others

6.3. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Competition by Key Manufacturers

8.1. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx): Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Qiagen NV

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. GE Healthcare

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Agilent Technologies

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. F Hoffman La Roche

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Foundation Medicine

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Thermo Fisher Scientific Inc.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Leica Biosystems Nussloch GmBH

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Pfizer

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market

Figure 4: Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market: Drivers

Figure 5: Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market: Challenges

Figure 6: Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market: Trends

Figure 7: Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market: Opportunity

Figure 8: Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market: Restraint

Figure 9: Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Value (USD Million) By Region

Figure 15: Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Value (USD Million) By Region

Figure 23: Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

69 items

Table 1: Market Segmentation Analysis

Table 2: Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Value (USD Million) By Region

Table 10: Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Qiagen NV Basic Information And Sales Area

Table 31: Qiagen NV. Products Portfolio

Table 32: GE Healthcare Basic Information And Sales Area

Table 33: GE Healthcare. Products Portfolio

Table 34: Agilent Technologies Basic Information And Sales Area

Table 35: Agilent Technologies. Products Portfolio

Table 36: F Hoffman La Roche Basic Information And Sales Area

Table 37: F Hoffman La Roche. Products Portfolio

Table 38: Foundation Medicine Basic Information And Sales Area

Table 39: Foundation Medicine. Products Portfolio

Table 40: Thermo Fisher Scientific Inc. Basic Information And Sales Area

Table 41: Thermo Fisher Scientific Inc.. Products Portfolio

Table 42: Leica Biosystems Nussloch GmBH Basic Information And Sales Area

Table 43: Leica Biosystems Nussloch GmBH. Products Portfolio

Table 44: Pfizer Basic Information And Sales Area

Table 45: Pfizer. Products Portfolio

Table 46: Global Market Value (USD Million) (2025-2032) By Application

Table 47: Global Market Share (%) By Application (2032)

Table 48: Global Market Value (USD Million) (2025-2032) By Types

Table 49: Global Market Share (%) By Types (2032)

Table 50: Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Value (USD Million) By Region

Table 51: Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share (%) By Region (2025-2032)

Table 52: North America Market Value (USD Million) (2025-2032) By Country

Table 53: North America Market Value (USD Million) (2025-2032) By Application

Table 54: North America Market Value (USD Million) (2025-2032) By Types

Table 55: Europe Market Value (USD Million) (2025-2032) By Country

Table 56: Europe Market Value (USD Million) (2025-2032) By Application

Table 57: Europe Market Value (USD Million) (2025-2032) By Types

Table 58: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 59: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 61: South America Market Value (USD Million) (2025-2032) By Country

Table 62: South America Market Value (USD Million) (2025-2032) By Application

Table 63: South America Market Value (USD Million) (2025-2032) By Types

Table 64: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 65: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 67: Research Programs/Design For This Report

Table 68: Key Data Information From Secondary Sources

Table 69: Key Data Information From Primary Sources

FAQs

1. What is the current market size?

The Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market size was valued at USD 1.2 billion in 2023, driven by advancements in personalized medicine and increasing adoption of precision therapies across oncology and other therapeutic areas.

2. What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, fueled by rising demand for targeted therapies and supportive regulatory frameworks like FDA’s companion diagnostic approvals.

3. What are the key drivers?

Key drivers include the shift toward personalized medicine, growing cancer incidence, and advancements in next-generation sequencing (NGS) and AI-based biomarker discovery technologies.

4. What challenges does the market face?

High costs of genetic testing, reimbursement limitations, and the need for robust clinical validation of biomarkers hinder widespread adoption despite technological progress.

5. Who are the regional leaders?

North America leads with 45% market share in 2023, driven by strong R&D investments and a mature healthcare ecosystem, followed by Europe and Asia-Pacific due to expanding biopharma activities.

6. Which companies dominate the market?

Top players include Roche, Qiagen, Thermo Fisher Scientific, and PerkinElmer, who leverage advanced diagnostics platforms and strategic partnerships to strengthen market presence.

7. What future opportunities exist?

Emerging opportunities lie in decentralized diagnostic solutions, AI-integrated pharmacogenomics, and expanding applications beyond oncology, such as in autoimmune and rare diseases.

8. How is technology shaping the sector?

Next-generation sequencing and CRISPR-based diagnostics are revolutionizing biomarker identification, while digital health tools enhance data analysis and real-world evidence generation for personalized therapies.

9. What is the regulatory landscape?

Regulatory clarity remains fragmented, but initiatives like the FDA’s 21st Century Cures Act and EMA’s adaptive pathways are accelerating CDx approvals, ensuring safety while fostering innovation.

Contact for Full Report

Loading report content...

Pharmacogenomics Technology &amp; Theranostics &amp; Companion Diagnostics (CDx) Market Growing at CAGR — 2026 Report

Market Snapshot

Pharmacogenomics Technology &amp; Theranostics &amp; Companion Diagnostics (CDx) Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Segmentation

Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current market size?

2. What is the expected growth rate?

3. What are the key drivers?

4. What challenges does the market face?

5. Who are the regional leaders?

6. Which companies dominate the market?

7. What future opportunities exist?

8. How is technology shaping the sector?

9. What is the regulatory landscape?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Pharmacogenomics Technology &amp; Theranostics &amp; Companion Diagnostics (CDx) Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Segmentation

Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current market size?

2. What is the expected growth rate?

3. What are the key drivers?

4. What challenges does the market face?

5. Who are the regional leaders?

6. Which companies dominate the market?

7. What future opportunities exist?

8. How is technology shaping the sector?

9. What is the regulatory landscape?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Growing at CAGR — 2026 Report

Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Overview

Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Overview